您现在的位置是:erlang b formula > Focus
【i accidentally drank from a straw after wisdom teeth】Cara Therapeutics to Announce First Quarter 2020 Financial Results on May 11, 2020
erlang b formula2024-09-29 12:30:06【Focus】9人已围观
简介STAMFORD, Conn., May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (CARA), a biopharmaceutica i accidentally drank from a straw after wisdom teeth
STAMFORD,i accidentally drank from a straw after wisdom teeth Conn., May 04, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (
CARA
), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, May 11, 2020, at 4:30 p.m. ET to report first quarter 2020 financial results and provide a corporate update.
To participate in the conference call, please dial (855) 445-2816 (domestic) or (484) 756-4300 (international) and refer to conference ID 3875739. A live webcast of the call can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at
www.CaraTherapeutics.com
.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA is in Phase 2 trials for the treatment of pruritus in patients with CKD, atopic dermatitis and primary biliary cholangitis (PBC).
The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
INVESTOR CONTACT:
Jane Urheim
Stern Investor Relations, Inc.
212-362-1200
View comments
很赞哦!(9)
相关文章
- How to Rise Above an ACT, SAT Test Score Plateau
- The Top 10 Cryptocurrencies Aren’t The Most Actively Developed
- BRIEF-Jiangsu Zijin Rural Commercial Bank's Share Trade To Debut On Jan 3 On Shanghai Exchange
- BIC: HACO Industries Kenya Closing
- Teleste's financial reporting and Annual General Meeting in 2021
- Kellogg Beats on Earnings, Cereals Let Down Sales
- The Lotus Elise GT1 Is Not Your Average Elise
- Effort to Close Double Jeopardy 'Loophole' in NY Revived in New Session
- Merck (MRK) Stock Moves -0.81%: What You Should Know
- Italy PM, economy minister personally following Carige developments
热门文章
站长推荐
Clarivate Analytics Plc (CCC) Q1 Earnings and Revenues Miss Estimates
Is Concho Resources Inc. (NYSE:CXO) Excessively Paying Its CEO?
BRIEF-Rizhao Port's Controlling Shareholder's Unit Wins Project For 243.5 Million Yuan
GM electric vehicle tax credit phase-out to begin this year: Report
BRIEF-CITIC Ltd Updates On The Proposed Restructuring Of Daye Special Steel
USD starts the New Year on the front foot
The 3 Top Retail Stocks to Own in 2019
Business Highlights
友情链接
- How Serco Group plc (LON:SRP) Can Impact Your Portfolio Volatility
- The Hague Evidence Convention’s Rarely-Used Private Commissioner Provision May Be a Viable Option for Cross-Border Discovery
- Epiphany: When Is Kings Day 2019? What Is It?
- Morning Brief: Congressional leaders attend White House border briefing
- You Can Own This Lotus Cortina Raced by Some of the World's Greatest Drivers
- DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Apogee Enterprises, Inc. (APOG) and Lead Plaintiff Deadline - January 4, 2019
- Cryptocurrencies Advance; India Shelves Plans to Launch Digital Token
- Italy's Carige administrator says no merger in sight for bank - TV
- S&P 500 Price Forecast – stock markets find support after initial negativity
- Cee Lo Holds Court at Primary Wave Pre-Grammy Party, Larry Mestel Calls RoccStar, Trevor Jackson ‘The Future’